Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-methyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline
- Development stage
- Preclinical
- Lead developer
- Showa Pharmaceutical University
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
1-methyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline (1-Me-N-propargyl-TIQ) is a small molecule research compound investigated for its neuroprotective properties, particularly in the context of Parkinson's disease. It is a derivative of the endogenous neurotoxin 1,2,3,4-tetrahydroisoquinoline (TIQ), modified with an N-propargyl group to mimic the structure of the monoamine oxidase (MAO) inhibitor selegiline. Research, primarily conducted at Showa Pharmaceutical University, indicates that the compound prevents MPTP-induced dopaminergic neurodegeneration and striatal dopamine depletion in animal models. Its mechanism involves the inhibition of MPP+-induced cell death and the preservation of dopamine transporter (DAT) expression and tyrosine hydroxylase-positive cells in the substantia nigra.
- Other names
- 1-methyl-N-propargyl-tetrahydroisoquinoline
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on 1-methyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-methyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline.